GSA Capital Partners LLP Has $1.31 Million Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Key Points

• GSA Capital Partners LLP significantly increased its stake in Amphastar Pharmaceuticals, owning 45,297 shares after a 159.8% increase during Q1, valued at approximately $1.31 million.
• Other institutional investors also raised their positions in Amphastar, with TD Asset Management Inc increasing holdings by 20.2% and Boston Trust Walden Corp by 24.2% during the same quarter.
• An analyst downgrade has affected the stock’s outlook, with JPMorgan reducing its price target from $45.00 to $30.00, while the average rating has been set at "Hold" with a consensus target price of $32.33.

GSA Capital Partners LLP increased its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 159.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 45,297 shares of the company's stock after acquiring an additional 27,863 shares during the period. GSA Capital Partners LLP owned approximately 0.10% of Amphastar Pharmaceuticals worth $1,313,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of AMPH. Signaturefd LLC increased its stake in Amphastar Pharmaceuticals by 147.7% during the 1st quarter. Signaturefd LLC now owns 872 shares of the company's stock valued at $25,000 after buying an additional 520 shares during the period. IFP Advisors Inc acquired a new position in shares of Amphastar Pharmaceuticals during the first quarter valued at approximately $34,000. GF Fund Management CO. LTD. bought a new stake in Amphastar Pharmaceuticals during the fourth quarter worth approximately $38,000. GAMMA Investing LLC lifted its position in Amphastar Pharmaceuticals by 46.6% in the first quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock worth $39,000 after purchasing an additional 424 shares during the period. Finally, Tower Research Capital LLC TRC lifted its position in Amphastar Pharmaceuticals by 43.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after purchasing an additional 348 shares during the period. 65.09% of the stock is currently owned by institutional investors.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ:AMPH traded up $0.26 on Friday, reaching $21.21. 440,154 shares of the company traded hands, compared to its average volume of 454,819. The company has a debt-to-equity ratio of 0.80, a current ratio of 2.95 and a quick ratio of 2.02. The stock has a market capitalization of $999.84 million, a PE ratio of 7.68 and a beta of 0.76. The company's 50 day moving average is $23.71 and its 200-day moving average is $26.76. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $20.39 and a fifty-two week high of $53.96.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on AMPH. Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Wells Fargo & Company dropped their price target on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. Finally, JPMorgan Chase & Co. restated a "neutral" rating and set a $30.00 price objective (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $32.33.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.